Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions frequently mention the improved overall survival rates associated with ONC201, with one poster noting that it nearly doubles survival rates for patients. Another user emphasized that this research represents a major step forward in the fight against DIPG, using phrases like 'incredible step forward' to highlight the transformative potential of the findings. The enthusiastic language and supportive tone across these discussions help convey a strong sense of hope and optimism regarding the treatment's implications in pediatric oncology.
The overall tone of the discussions is highly supportive of the findings from the publication, indicating strong agreement with the research conclusions.
The posts reflect a significant level of curiosity and relevance, with many users expressing enthusiasm about the clinical implications of ONC201.
While some posts share general announcements, others delve into specific clinical outcomes and comparisons to previous trials, suggesting moderate engagement depth.
Many users believe that the findings will greatly impact treatment options for pediatric patients, emphasizing the potential for improved survival rates.
Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways @KoschmannLab @vennetilab https://t.co/3yJm8qxteG @umichmedicine @UMRogelCancer @MottChildren #DMG #DIPG https://t.co/mMlIS2N91v
Clinical efficacy of ONC201 in H3K27M-DMG, by @vennetilab, Abed Rahman Kawakibi, Sunjong Ji, @sebastianw, Stefan Sweha, Mateus Mota, Matthew Pun, Sharon Gardner, @OdiaYazmin, @KoschmannLab et al. https://t.co/GWtUPsav42 @umichmedicine @UMRogelCancer @MottChildren #DMG #DIPG https://t.co/caRNiVXOfh
Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways https://t.co/Zxx1eekixG
November issue— Clinical efficacy of ONC201 in H3K27M-#DMG, by @vennetilab, @AbedKawakibi, Sunjong Ji, @sebastianw, Stefan Sweha, Mateus Mota, Matthew Pun, Sharon Gardner, @OdiaYazmin, @KoschmannLab et al. https://t.co/fZlXzyjYmt @umichmedicine @UMRogelCancer @MottChildren #DIPG https://t.co/HcD366l8nR
Now online in @CD_AACR "Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways". Excited to have worked on this study with the amazing team from @KoschmannLab and @vennetilab.
Read the paper— Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways, by @KoschmannLab, @vennetilab et al. https://t.co/LswKvOd0i5 @umichmedicine @UMRogelCancer @MottChildren #DMG #DIPG https://t.co/vcSFhXTfQk https://t.co/N8hWNpEoFk
A new study in Cancer Discovery shows ONC201 significantly improves survival for H3K27M-mutant DMG patients. Administered after radiation, the median survival rate was 22 months, with one-third living beyond two years…
This week's news highlights significant advancements in cancer treatment and neurological research, including the promising efficacy of ONC201 for H3K27M-mutant diffuse midline gliomas, which disrupts metabolic and…
RT @AbedKawakibi: Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Effi…
@StasLazarev JCO paper excluded DIPG but earlier work from Koschmann group included pediatric DIPG pts showing median OS of ~22 months which compares very favorably to prior COG trials (ie PNOC003 had OS of ~13 months) https://t.co/hy2YfQ258o https://t.co/xoK4Bh6Fhk
RT @CD_AACR: Read the study that was part of the basis for this new approval: "Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline…
Read the study that was part of the basis for this new approval: "Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways" https://t.co/zv5NdpGnFr https://t.co/sEos5m7OHS
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
@Hakanzt50881607 @DKFZ https://t.co/6vbjGxNVcP
RT @InnovOncology: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and…
RT @InnovOncology: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and…
RT @InnovOncology: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and…
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways @CD_AACR @AACR @OncoAlert @oncodaily @SciLife_ @InnovOncology #MedEd #MedX #Oncology #AACR2024 #AACR24 https://t.co/2HsiUM1Quo
Parallelly, patients with H3K27M-mutant DMG who underwent the imipridone ONC201 treatment exhibited enhanced outcomes when compared to historical data. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways. More info here: https://t.co/AVPheT7ciE (4/15)
RT @CD_AACR: November issue— Clinical efficacy of ONC201 in H3K27M-#DMG, by @vennetilab, @AbedKawakibi, Sunjong Ji, @sebastianw, Stefan Swe…
November issue— Clinical efficacy of ONC201 in H3K27M-#DMG, by @vennetilab, @AbedKawakibi, Sunjong Ji, @sebastianw, Stefan Sweha, Mateus Mota, Matthew Pun, Sharon Gardner, @OdiaYazmin, @KoschmannLab et al. https://t.co/0aIUiOQWDQ @umichmedicine @UMRogelCancer @MottChildren #DIPG https://t.co/cfeeNejM9f
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways https://t.co/MX4C1oWXDo
H3K27M変異拡散中線神経膠腫におけるONC201の臨床的有効性は、統合された代謝およびエピジェネティックな経路の破壊によって駆動される | がん発見 | 米国がん研究協会 https://t.co/Drowv4Whij
RT @CD_AACR: November issue— Clinical efficacy of ONC201 in H3K27M-#DMG, by @vennetilab, @AbedKawakibi, Sunjong Ji, @sebastianw, Stefan Swe…
RT @CD_AACR: November issue— Clinical efficacy of ONC201 in H3K27M-#DMG, by @vennetilab, @AbedKawakibi, Sunjong Ji, @sebastianw, Stefan Swe…
RT @CD_AACR: November issue— Clinical efficacy of ONC201 in H3K27M-#DMG, by @vennetilab, @AbedKawakibi, Sunjong Ji, @sebastianw, Stefan Swe…
RT @CD_AACR: November issue— Clinical efficacy of ONC201 in H3K27M-#DMG, by @vennetilab, @AbedKawakibi, Sunjong Ji, @sebastianw, Stefan Swe…
November issue— Clinical efficacy of ONC201 in H3K27M-#DMG, by @vennetilab, @AbedKawakibi, Sunjong Ji, @sebastianw, Stefan Sweha, Mateus Mota, Matthew Pun, Sharon Gardner, @OdiaYazmin, @KoschmannLab et al. https://t.co/fZlXzyjYmt @umichmedicine @UMRogelCancer @MottChildren #DIPG https://t.co/HcD366l8nR
RT @DrBaileeSliker: If you want more on gliomas after the talks at the afternoon session of #TumourLandscape23, don't miss this @CD_AACR by…
RT @DrBaileeSliker: If you want more on gliomas after the talks at the afternoon session of #TumourLandscape23, don't miss this @CD_AACR by…
RT @DrBaileeSliker: If you want more on gliomas after the talks at the afternoon session of #TumourLandscape23, don't miss this @CD_AACR by…
RT @DrBaileeSliker: If you want more on gliomas after the talks at the afternoon session of #TumourLandscape23, don't miss this @CD_AACR by…
If you want more on gliomas after the talks at the afternoon session of #TumourLandscape23, don't miss this @CD_AACR by @CarlKoschmann, @vennetilab, et al on the clinical efficacy of ONC201 in H3K27M-DMG https://t.co/ugY6NorWin @chadtough https://t.co/CtVIIJWOc2
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
https://t.co/lolgP08Tpg https://t.co/yjNCJnk0Pp
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
RT @MattDun17: @KoschmannLab @vennetilab @AbedKawakibiMD #sunny @sebastianw et al., in the proofs we added the clinical finding as this pap…
@KoschmannLab @vennetilab @AbedKawakibiMD #sunny @sebastianw et al., in the proofs we added the clinical finding as this paper was submitted before we all met up in Ann Arbor and accepted some time ago https://t.co/31CAa43Zso
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways https://t.co/CuiYRdcIBl
RT @CD_AACR: Clinical efficacy of ONC201 in H3K27M-DMG, by @vennetilab, Abed Rahman Kawakibi, Sunjong Ji, @sebastianw, Stefan Sweha, Mateus…
RT @CD_AACR: Clinical efficacy of ONC201 in H3K27M-DMG, by @vennetilab, Abed Rahman Kawakibi, Sunjong Ji, @sebastianw, Stefan Sweha, Mateus…
Clinical efficacy of ONC201 in H3K27M-DMG, by @vennetilab, Abed Rahman Kawakibi, Sunjong Ji, @sebastianw, Stefan Sweha, Mateus Mota, Matthew Pun, Sharon Gardner, @OdiaYazmin, @KoschmannLab et al. https://t.co/GWtUPsav42 @umichmedicine @UMRogelCancer @MottChildren #DMG #DIPG https://t.co/caRNiVXOfh
Wow @CD_AACR: 84 coauthors! Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways | Cancer Discovery | American Association for Cancer Research https://t.co/r5k104Bioy
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
腫瘍細胞によって産生されるL-2HGと呼ばれる代謝産物が増加し、それが腫瘍を定義するエピジェネティックシグナルを逆転させ、腫瘍細胞の分化を促進し、分裂を減少させることがわかりました。https://t.co/vvFeu787io
https://t.co/8Dcu4ycpIp
RT @sebastianw: Now online in @CD_AACR "Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of int…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @AbedKawakibiMD: Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Ef…
RT @sebastianw: Now online in @CD_AACR "Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of int…
Trend up+4: Venneti S, ..., Koschmann C (Cancer Discov) __Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways__ https://t.co/fZBoUMjsCS
RT @sebastianw: Now online in @CD_AACR "Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of int…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
ONC201 nearly doubled survival for patients with H3K27M-mutated diffuse midline gliomas (DMG https://t.co/QjtdjkXQKB
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @CD_AACR: Read the paper— Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Met…
RT @AbedKawakibiMD: Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Ef…
RT @CD_AACR: Read the paper— Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Met…
RT @DrBaileeSliker: Don't miss the new @CD_AACR paper discussed here featuring these amazing @chadtough researchers! Find the link here: ht…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @AbedKawakibiMD: Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Ef…
RT @DrBaileeSliker: Don't miss the new @CD_AACR paper discussed here featuring these amazing @chadtough researchers! Find the link here: ht…
Don't miss the new @CD_AACR paper discussed here featuring these amazing @chadtough researchers! Find the link here: https://t.co/FERWd3tGfL https://t.co/aO4MRsYjsn
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @CD_AACR: Read the paper— Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Met…
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
RT @CD_AACR: Read the paper— Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Met…
RT @CD_AACR: Read the paper— Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Met…
RT @AbedKawakibiMD: Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Ef…
RT @CD_AACR: Read the paper— Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Met…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @CD_AACR: Read the paper— Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Met…
RT @sebastianw: Now online in @CD_AACR "Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of int…
RT @CD_AACR: Read the paper— Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Met…
RT @AbedKawakibiMD: Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Ef…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
Read the paper— Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways, by @KoschmannLab, @vennetilab et al. https://t.co/LswKvOd0i5 @umichmedicine @UMRogelCancer @MottChildren #DMG #DIPG https://t.co/vcSFhXTfQk https://t.co/N8hWNpEoFk
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @chadtough: ChadTough Defeat DIPG Foundation is honored to support this work and witness this incredible step forward in the fight to #D…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
RT @AbedKawakibiMD: Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Ef…
RT @AbedKawakibiMD: Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Ef…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @sebastianw: Now online in @CD_AACR "Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of int…
great job by @koschmannlab congratulations! https://t.co/cPo6cvmNKZ https://t.co/lBeFJykRZr
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @sebastianw: Now online in @CD_AACR "Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of int…
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @AbedKawakibiMD: Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Ef…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @AbedKawakibi: Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Effi…
RT @sebastianw: Now online in @CD_AACR "Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of int…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @chadtough: A new manuscript published today reports ONC201 nearly doubles survival rates for patients with DIPG/DMG. Carl Koschmann, M…
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
Now online in @CD_AACR "Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways". Excited to have worked on this study with the amazing team from @KoschmannLab and @vennetilab.
Link to article: https://t.co/8VLVMNDPwl
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
RT @UMRogelCancer: For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric…
Excited to finally share this important work! Thanks to @KoschmannLab @vennetilab Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways https://t.co/Zxx1eekixG
RT @vennetilab: Super excited to share our paper in collaboration with @KoschmannLab on ONC201 in H3K27M #DIPG #DMG! ONC201 is therapeuti…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
ChadTough Defeat DIPG Foundation is honored to support this work and witness this incredible step forward in the fight to #DefeatDIPG. Watch the full video to learn about the next steps to build upon this research: https://t.co/eWpiPv0i23
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
RT @ElizSMcKenna: Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of I…
Now online in @CD_AACR: Clinical Efficacy of ONC201 in H3K27M-mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways @KoschmannLab @vennetilab https://t.co/3yJm8qxteG @umichmedicine @UMRogelCancer @MottChildren #DMG #DIPG https://t.co/mMlIS2N91v